NAB2

NAB2 is a neuroprotectant that targets the small GTPase Rab1a. NAB2 selectively binds to the GDP-bound form of Rab1a and protects multiple cell types from α-synuclein toxicity by increasing Rab1a expression. Rab1a regulates ER-to-Golgi trafficking and mediates endosomal trafficking events of the E3 ubiquitin ligase Rsp5/Nedd4. NAB2 stimulates ubiquitination of related proteins in a Nedd4-dependent manner and rescues α-synuclein-associated trafficking defects associated with early-onset Parkinson's disease[1][2][3].

Product Specifications

CAS Number

[1504588-00-4]

UNSPSC

12352005

Hazard Statement

H315-H319-H335

Target

α-synuclein

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/nab2.html

Purity

99.69

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC1=C(C=C(C)C=C1)N2C3=CC=C(C(NCC4=C(C=CC=C4)Cl)=O)C=C3N=C2

Molecular Formula

C23H20ClN3O

Molecular Weight

389.88

Precautions

P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362-P403+P233-P405-P501

References & Citations

[1]Tardiff DF, et al. Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science. 2013;342 (6161) :979-983.|[2]Hatstat AK, et al. Chemoproteomic-enabled characterization of small GTPase Rab1a as a target of an N-arylbenzimidazole ligand's rescue of Parkinson's-associated cell toxicity. RSC Chem Biol. 2021 Nov 9;3 (1) :96-111.